Rothoerl, R.; Tomelden, J.; Alt, E.U. Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain. J. Pers. Med.2023, 13, 436.
Rothoerl, R.; Tomelden, J.; Alt, E.U. Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain. J. Pers. Med. 2023, 13, 436.
Rothoerl, R.; Tomelden, J.; Alt, E.U. Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain. J. Pers. Med.2023, 13, 436.
Rothoerl, R.; Tomelden, J.; Alt, E.U. Safety and Efficacy of Autologous Stem Cell Treatment for Facetogenic Chronic Back Pain. J. Pers. Med. 2023, 13, 436.
Abstract
Background: Chronic Back Pain due to Facet Joint Syndrome is a common and debilitating con-dition. Advances in regenerative medicine have shown that Autologous Unmodified Adipose Tissue-Derived Regenerative Cells (ADRC) provide several beneficial effects [1,2]. These regen-erative cells can differentiate into various tissues [3] and exhibit a strong anti-inflammatory po-tential. ADRCs can be obtained from a small amount of fatty tissue derived from the patient´s abdominal fat. Methods: We report long-term results of 37 patients (age 31-78 years, mean 62.5) suffering from “Facet Joint Syndrome” The pathology was confirmed by clinical, radiological examinations and fluoroscopically guided test injections. Then liposuction was performed. 50-100 cc of fat were harvested. To recover stem cells from adipose tissue, we use the CE-certified Transpose RT™ system from InGeneron GmbH. The cells were then injected under fluoroscopic control in the periarticular fat. Follow-up examinations were performed at one week 1 and 5 years. Results: Every patient reported improved VAS pain at any follow-up (1 week, 1, and 5 years) with ADRCs compared to the baseline. Conclusion: Our observational data indicate that facet joint syndrome patients treated with unmodified adipose tissue-derived regenerative cells experience improved quality of life in the long term.
Medicine and Pharmacology, Anesthesiology and Pain Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
